Filing Details

Accession Number:
0001610717-24-000236
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-05-09 16:03:51
Reporting Period:
2024-05-06
Accepted Time:
2024-05-09 16:03:51
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1437402 Ardelyx Inc. ARDX Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1917819 Ora Robert Felsch C/O Ardelyx, Inc.
400 Fifth Avenue, Suite 210
Waltham MA 02451
See Remarks No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-05-06 79,101 $0.84 263,935 No 4 M Direct
Common Stock Acquisiton 2024-05-06 40,000 $2.75 303,935 No 4 M Direct
Common Stock Disposition 2024-05-06 152,988 $8.81 150,947 No 4 S Direct
Common Stock Disposition 2024-05-06 55,000 $8.80 95,947 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2024-05-06 79,101 $0.00 79,101 $0.84
Common Stock Stock Option (Right to Buy) Disposition 2024-05-06 40,000 $0.00 40,000 $2.75
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
61,525 2032-02-01 No 4 M Direct
80,000 2033-01-05 No 4 M Direct
Footnotes
  1. This transaction was executed in multiple trades in prices ranging from $8.63 to $9.01, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  2. Twenty Five Percent (25%) of the shares subject to the option vest on February 1, 2023 and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
  3. The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 5, 2023, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.